Crinetics Pharmaceuticals (CRNX) Current Deferred Revenue (2022 - 2026)

Crinetics Pharmaceuticals' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 80.5% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a 80.5% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 82.05% from the prior year.
• Current Deferred Revenue climbed to $1.3 million in Q1 2026 per CRNX's latest filing, from $1.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $9.4 million in Q2 2022 and bottomed at $1.2 million in Q4 2025.
• The 5-year median for Current Deferred Revenue is $6.8 million (2023), against an average of $5.1 million.
• Across the five-year window, Current Deferred Revenue soared 193.36% in 2023 and slumped 82.05% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $8.3 million in 2022, then decreased by 18.4% to $6.8 million in 2023, then grew by 1.09% to $6.9 million in 2024, then slumped by 82.05% to $1.2 million in 2025, then increased by 2.91% to $1.3 million in 2026.
• Per Business Quant, the three latest CRNX Current Deferred Revenue figures stand at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.6 million (Q3 2025).